DuPont Decomposition

Why does AUROPHARMA earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

9.3% = 10.5% × 0.57 × 1.54

Latest: FY2026

Profitability

Net Margin

10.5%

11.3% →10.5%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.57x

0.69x →0.57x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.54x

1.38x →1.54x

Assets funded by equity vs debt

Trend Analysis

ROE declined by 1.5 pp over 5 years. Driven by asset turnover declining (0.69x → 0.57x).

Historical Decomposition

Last 5 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr11.3%0.691.3810.8%
FY20230Cr0Cr7.8%0.621.497.2%
FY20240Cr0Cr11.1%0.641.5110.6%
FY20250Cr0Cr11.1%0.631.5210.7%
FY20260Cr0Cr10.5%0.571.549.3%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for AUROPHARMA

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

AUROPHARMA DuPont Analysis — ROE 9.3% | YieldIQ